EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Antimalarial cytoskeletal targeting with broad apicomplexan activity

Darshan V Trivedi, Anastasia Karabina, Tiantian Jiang iD, Daisy Chen, Nimisha Mittal, Tonnie Huijs, Rianne van der Laak, Jin H Jeon, Tomas Yeo iD, Dihia Moussaoui, James P Robblee, Marianna Akey und 30 weitere

Proceedings of the National Academy of Sciences · 2026

DOI: 10.1073/pnas.2608709123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Darshan V Trivedi und 41 weiteren Autor:innen. Beteiligte Einrichtung: Kainomyx Inc., Palo Alto, CA 94304. Hauptthemen laut MEDLINE: Plasmodium falciparum, Antimalarials, Cytoskeleton, Nonmuscle Myosin Type IIA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gates Foundation, NIAID NIH HHS, Medicines for Malaria Venture (MMV).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malaria is a devastating disease that resulted in an estimated 610,000 deaths in 2024, the majority being children under the age of five. Here, we use KNX-115 to illustrate multistage antiparasitic activity upon targeting the cytoskeletal enzyme Plasmodium falciparum myosin A (PfMyoA). KNX-115 inhibits purified actin-activated ATPase with a potency in the low nanomolar range and >50-fold selectivity against cardiac, skeletal, and smooth muscle myosins. KNX-115 traps PfMyoA in a state that binds weakly to actin. A 2.35 Å resolution structure of KNX-115 bound to PfMyoA reveals critical interactions contributing to its mechanism of action. Importantly, in vitro evolution data reveal that KNX-115 engages PfMyoA as a sole cellular target. Inhibiting PfMyoA blocks the development of the blood and liver stages of laboratory strains of P. falciparum , with no liver cell toxicity, sporozoite cell traversal and motility, and sporozoite development in the mosquito. Inhibiting PfMyoA completely kills parasites after 96 h of treatment. Furthermore, KNX-115 is equally effective at inhibiting a panel of Plasmodium strains resistant to experimental and marketed antimalarials and shows inhibitory activity against P. falciparum circulating isolates from the Brazilian Amazon. Inhibiting PfMyoA with KNX-115 also blocks the blood stage of a laboratory strain of Plasmodium vivax . In line with the evolutionary identity of MyoA among various apicomplexan parasites, KNX-115 also inhibits Cryptosporidium and Eimeria MyoA in vitro and is an effective inhibitor of Cryptosporidium , Toxoplasma, and Eimeria cellular growth, with EC 50 s similar to those found for blood and liver stage Plasmodium .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasmodium falciparumAntimalarialsCytoskeletonNonmuscle Myosin Type IIAAnimalsHumansProtozoan ProteinsMalaria, FalciparumActins

Stichwörter der Autor:innen

MyoA inhibitormalariamyosinparasitic diseases

Substanzen

AntimalarialsNonmuscle Myosin Type IIAProtozoan ProteinsActins

Autor:innen und Institutionen

  • Kainomyx Inc., Palo Alto, CA 94304.
  • Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA 92093.
  • TropIQ Health Sciences, Nijmegen 6534 AT, The Netherlands.
  • Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032.
  • Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, NY 10032.
  • Cell Biology and Cancer Unit, Structural Motility, Institut Curie, UMR144 CNRS, Paris Science & Letters Research University, Paris 75005, France.

ORCID-Profile: Tiantian Jiang, Tomas Yeo, Benoît Laleu, Rafael Victorio Carvalho Guido, L David Sibley, Anne Houdusse, Elizabeth A Winzeler, James A Spudich

Förderung

  • Gates Foundation
  • NIAID NIH HHS
  • Medicines for Malaria Venture (MMV)
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
  • Bill & Melinda Gates Foundation
  • Bill and Melinda Gates Foundation

Zitieren

APA

Trivedi, D. V., Karabina, A., Jiang, T., Chen, D., Mittal, N., Huijs, T., van der Laak, R., Jeon, J. H., Yeo, T., Moussaoui, D., Robblee, J. P., Akey, M., Freese, M., Fuller, L., Bergnes, G., Racca, A., Wander, H., Jung, S., Ouchida, S., …, & Spudich, J. A. (2026). Antimalarial cytoskeletal targeting with broad apicomplexan activity. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2608709123

Vancouver

Trivedi DV, Karabina A, Jiang T, Chen D, Mittal N, Huijs T, et al. Antimalarial cytoskeletal targeting with broad apicomplexan activity. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2608709123

BibTeX
@article{Trivedi2026,
  author = {Trivedi, Darshan V and Karabina, Anastasia and Jiang, Tiantian and Chen, Daisy and Mittal, Nimisha and Huijs, Tonnie and van der Laak, Rianne and Jeon, Jin H and Yeo, Tomas and Moussaoui, Dihia and Robblee, James P and Akey, Marianna and Freese, Matthew and Fuller, Lorraine and Bergnes, Gustave and Racca, Alice and Wander, Heba and Jung, Seongwon and Ouchida, Stephanie and Ruijgrok, Paul V and Song, Dan and Spudich, Annamma and Ruppel, Kathleen M and Nag, Suman and Mueller-Dieckmann, Christoph and Burrows, Jeremy N and Laleu, Benoît and Guido, Rafael Victorio Carvalho and Campos Aguiar, Anna Caroline and Pereira, Dhelio Batista and Wittlin, Sergio and Mukherjee, Partha and Chakraborty, Arnish and Aggrey, Samuel E and Robert-Paganin, Julien and Trybus, Kathleen M and Sibley, L David and Houdusse, Anne and Fidock, David A and Dechering, Koen J and Winzeler, Elizabeth A and Spudich, James A},
  title = {Antimalarial cytoskeletal targeting with broad apicomplexan activity},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  doi = {10.1073/pnas.2608709123}
}
Kostenlos starten →